Use of an Insulin Bolus Advisor Improves Glycemic Control in Multiple Daily Insulin Injection (MDI) Therapy Patients With Suboptimal Glycemic Control
| Autor: | David A. Cavan, Christopher G. Parkin, Claudia Vogel, Matthias Axel Schweitzer, Robin Wagner, Iris Vesper, Iain Cranston, Ralph Ziegler, Walter Koehler, Bettina Petersen, Katharine D. Barnard, Jacqueline Ryder |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
Insulin pump
Adult Blood Glucose Male medicine.medical_specialty Dose Adolescent Emerging Technologies and Therapeutics Endocrinology Diabetes and Metabolism medicine.medical_treatment Type 2 diabetes Young Adult Bolus (medicine) Insulin Infusion Systems Diabetes mellitus Internal medicine Internal Medicine Medicine Humans Hypoglycemic Agents Insulin Prospective Studies Glycemic Original Research Advanced and Specialized Nursing Type 1 diabetes business.industry Blood Glucose Self-Monitoring medicine.disease Hypoglycemia Endocrinology Diabetes Mellitus Type 1 Diabetes Mellitus Type 2 Anesthesia Female business |
| Zdroj: | Diabetes Care |
| ISSN: | 1935-5548 0149-5992 |
| Popis: | OBJECTIVE Use of automated bolus advisors is associated with improved glycemic control in patients treated with insulin pump therapy. We conducted a study to assess the impact of using an insulin bolus advisor embedded in a blood glucose (BG) meter on glycemic control and treatment satisfaction in patients treated with multiple daily insulin injection (MDI) therapy. The study goal was to achieve >0.5% A1C reduction in most patients. RESEARCH DESIGN AND METHODS This was a 26-week, prospective, randomized, controlled, multinational study that enrolled 218 MDI-treated patients with poorly controlled diabetes (202 with type 1 diabetes, 16 with type 2 diabetes) who were 18 years of age or older. Participants had mean baseline A1C of 8.9% (SD, 1.2 [74 mmol/mol]), mean age of 42.4 years (SD, 14.0), mean BMI of 26.5 kg/m2 (SD, 4.2), and mean diabetes duration of 17.7 years (SD, 11.1). Control group (CNL) patients used a standard BG meter and manual bolus calculation; intervention group (EXP) patients used the Accu-Chek Aviva Expert meter with an integrated bolus advisor to calculate insulin dosages. Glucose data were downloaded and used for therapy parameter adjustments in both groups. RESULTS A total of 193 patients (CNL, n = 93; EXP, n = 100) completed the study. Significantly more EXP than CNL patients achieved >0.5% A1C reduction (56.0% vs. 34.4%; P < 0.01). Improvement in treatment satisfaction (Diabetes Treatment Satisfaction Questionnaire scale) was significantly greater in EXP patients (11.4 [SD, 6.0] vs. 9.0 [SD, 6.3]; P < 0.01). Percentage of BG values CONCLUSIONS Use of an automated bolus advisor resulted in improved glycemic control and treatment satisfaction without increasing severe hypoglycemia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|